 |
14 Diseases |  |
0 Trials |
|
0 Trials |  |
19 News |  |
- |||| Victoza (liraglutide) / Novo Nordisk, NN9828 / Novo Nordisk
Trial completion, Trial primary completion date: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function (clinicaltrials.gov) - Mar 13, 2019
P2, N=308, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | Trial primary completion date: Mar 2019 --> Aug 2018
- || Victoza (liraglutide) / Novo Nordisk, NN9828 / Novo Nordisk
Trial primary completion date: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function (clinicaltrials.gov) - Dec 21, 2018
P2, N=304, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | Trial primary completion date: Mar 2019 --> Aug 2018 Trial primary completion date: Nov 2018 --> Mar 2019
- ||| Victoza (liraglutide) / Novo Nordisk, NN9828 / Novo Nordisk
Enrollment closed: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function (clinicaltrials.gov) - Sep 25, 2017
P2, N=304, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Nov 2018 --> Mar 2019 Recruiting --> Active, not recruiting
- |||| Victoza (liraglutide) / Novo Nordisk, NN9828 / Novo Nordisk
Enrollment open: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function (clinicaltrials.gov) - Nov 14, 2015
P2, N=304, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Victoza (liraglutide) / Novo Nordisk, NN9828 / Novo Nordisk
New P2 trial: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function (clinicaltrials.gov) - May 13, 2015
P2, N=304, Not yet recruiting, Sponsor: Novo Nordisk A/S
- NN9828 / Novo Nordisk
Trial completion: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease (clinicaltrials.gov) - Dec 24, 2014
P2, N=53, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- NN9828 / Novo Nordisk
Enrollment closed, Enrollment change, Trial primary completion date: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease (clinicaltrials.gov) - Sep 5, 2014
P2, N=53, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=114 --> 53 | Trial primary completion date: Jul 2015 --> Dec 2014
- NN9828 / Novo Nordisk
Trial termination: An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Apr 6, 2014
P1, N=10, Terminated, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | N=114 --> 53 | Trial primary completion date: Jul 2015 --> Dec 2014 Completed --> Terminated
- NN9828 / Novo Nordisk
Enrollment change: An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Nov 24, 2013
P1, N=10, Terminated, Sponsor: Novo Nordisk A/S
Completed --> Terminated N=40 --> 10
- | NN9828 / Novo Nordisk
Trial completion: Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 8, 2013
P1, N=32, Completed, Sponsor: Novo Nordisk
N=40 --> 10 Active, not recruiting --> Completed
- |||| NN9828 / Novo Nordisk
Trial completion: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 5, 2013
P2, N=62, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- NN9828 / Novo Nordisk
Enrollment open: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease (clinicaltrials.gov) - Feb 14, 2013
P2, N=114, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | NN9828 / Novo Nordisk
New P2 trial: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease (clinicaltrials.gov) - Dec 13, 2012
P2, N=114, Recruiting, Sponsor: Novo Nordisk A/S
- NN9828 / Novo Nordisk
New P1 trial: An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Sep 18, 2012
P1, N=10, Terminated, Sponsor: Novo Nordisk A/S
- ||||| NN9828 / Novo Nordisk
New P2 trial: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 19, 2012
P2, N=62, Completed, Sponsor: Novo Nordisk
- | NN9828 / Novo Nordisk
New P1 trial: Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 26, 2012
P1, N=32, Completed, Sponsor: Novo Nordisk
- ||| NN9828 / Novo Nordisk
Trial completion: First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 27, 2012
P1, N=64, Completed, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Active, not recruiting --> Completed